FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges
1. FDA lifted clinical hold on VTVT's cadisegliatin program for Type 1 Diabetes. 2. CATT1 Phase 3 trial duration will shorten from 12 to 6 months. 3. Cadisegliatin shows promise as first oral therapy adjunct to insulin. 4. VTVT stock rose 66.70% following the FDA's announcement.